Baseline characteristics
| Characteristics | |
| Overall cases | 23 470 |
| Age, median (IQR) | 40 (30–54) |
| Sex, N (%) | |
| Male | 11 008 (46.9) |
| Female | 12 462 (53.1) |
| Date of treatment, N (%) | |
| 2017 | 3957 (16.9) |
| 2018 | 6486 (27.6) |
| 2019 | 7568 (32.2) |
| 2020 | 5459 (23.3) |
| Season, N (%) | |
| Spring | 4473 (19.1) |
| Summer | 5942 (25.3) |
| Autumn | 6322 (26.9) |
| Winter | 6733 (28.7) |
| Antibiotic regimens, N (%) | |
| Amoxicillin+furazolidone | 16 784 (71.5) |
| Amoxicillin+clarithromycin | 4182 (17.8) |
| Amoxicillin+levofloxacin | 309 (1.3) |
| Furazolidone+clarithromycin | 1669 (7.1) |
| Furazolidone+levofloxacin | 358 (1.5) |
| Clarithromycin+levofloxacin | 95 (0.4) |
| Others | 73 (0.3) |
| Duration, N (%) | |
| 10 | 5641 (24.0) |
| 12 | 1060 (4.5) |
| 14 | 16 769 (71.4) |
| Proton pump inhibitor, N (%) | |
| Rabeprazole10mg | 9654 (41.1) |
| Rabeprazole20mg | 21 (0.1) |
| Pantoprazole | 5815 (24.8) |
| Esomeprazole | 4811 (20.5) |
| Omeprazole | 2236 (9.5) |
| Lansoprazole | 933 (4.0) |